Merck to acquire SmartCells, a JDRF-funded company

December 02, 2010

NEW YORK - Today pharmaceutical company, Merck & Co., Inc. announced it will acquire SmartCells, Inc., a private biotech developing a glucose-responsive insulin whose proof-of-concept preclinical trials were partially funded by the Juvenile Diabetes Research Foundation (JDRF). SmartCells' product for the treatment of diabetes is designed to be a once-a-day injection that will maintain continuous, tight control of blood glucose levels while reducing the risk of hypoglycemia - like the pancreas does automatically in the absence of diabetes.

"This is exciting news for the diabetes research field and for JDRF. We believe this novel technology may lead to a practical solution to the real needs of people with diabetes," said Dr. Richard Insel, Chief Scientific Officer at JDRF. "We are pleased to see that SmartCells' technology has attracted the support of a leading pharmaceutical company that has the capacity to translate this opportunity to patients," added Insel.

JDRF funds critical gaps in the type 1 diabetes drug and device pipeline by supporting discovery and proof-of-concept research for innovative ideas that might otherwise remain unexplored. This is the sixth time that an early-stage product supported by JDRF has attracted the attention of industry, which has the expertise and resources to bring novel technologies to patients as quickly as possible. From 2008 to 2010, JDRF provided significant financial support - a total of over $1.5 million in funding - to the early-stage development of SmartInsulin™.

"A measure of JDRF's success is identifying and advancing promising research that may benefit people with type 1 diabetes," says Dr. Karin Hehenberger, Senior Vice President of Strategic Alliances at JDRF. "Merck's acquisition of SmartCells is an example of exactly this. A potentially transformational innovation has now been taken up by a large pharmaceutical company thanks in part to our support. This acquisition adds important financial and drug development capabilities to this promising glucose-responsive insulin."

Biotechnology companies often face challenges in advancing novel therapies beyond the initial stages of research. Through its Industry Discovery and Development Program (IDDP), JDRF identifies unique technologies that would not be advanced otherwise and partners with companies to test concepts and bring better treatments and therapeutics leading to a cure to patients faster. To date, JDRF has funded type 1 diabetes projects at 30 companies, committing approximately $72 million in research funding.

"Our funding to SmartCells was an important step in what has become the JDRF Insulin Initiative," noted Dr Sanjoy Dutta, Director of Glucose Control research at JDRF. "We are focused on supporting an effort towards the development of faster-acting insulins, other glucose-responsive insulins and novel therapies that will help people with diabetes maintain glucose control with less effort."

Diabetes is a large and growing challenge with as many as 3 million people in the United States living with type 1 diabetes and another 30,000 are newly-diagnosed each year. A recent CDC modeling report indicated that as many as one in three individuals could have diabetes, either type 1 or 2, by the year 2050. Better treatments are desperately needed to help people live better with the disease today as research continues toward an eventual cure.
About JDRF

JDRF is a leader in setting the agenda for diabetes research worldwide, and is the largest charitable funder of and advocate for type 1 diabetes research. The mission of JDRF is to find a cure for diabetes and its complications through the support of research. Type 1 diabetes is an autoimmune disease that strikes children and adults suddenly, and can be fatal. Until a cure is found, people with type 1 diabetes have to test their blood sugar and give themselves insulin injections multiple times or use a pump - each day, every day of their lives. And even with that intensive care, insulin is not a cure for diabetes, nor does it prevent its potential complications, which may include kidney failure, blindness, heart disease, stroke, and amputation. To help improve the lives of people with type 1 diabetes while working toward a cure, one of JDRF's research goals is to support research to develop products that can dramatically improve blood glucose control in people with type 1 diabetes so they can live healthier lives with less risk of developing disease-related complications.

Since its founding in 1970 by parents of children with type 1 diabetes, JDRF has awarded more than $1.5 billion to diabetes research, including more than $107 million last year. More than 80 percent of JDRF's expenditures directly support research and research-related education. For more information, please visit


Related Diabetes Articles from Brightsurf:

New diabetes medication reduced heart event risk in those with diabetes and kidney disease
Sotagliflozin - a type of medication known as an SGLT2 inhibitor primarily prescribed for Type 2 diabetes - reduces the risk of adverse cardiovascular events for patients with diabetes and kidney disease.

Diabetes drug boosts survival in patients with type 2 diabetes and COVID-19 pneumonia
Sitagliptin, a drug to lower blood sugar in type 2 diabetes, also improves survival in diabetic patients hospitalized with COVID-19, suggests a multicenter observational study in Italy.

Making sense of diabetes
Throughout her 38-year nursing career, Laurel Despins has progressed from a bedside nurse to a clinical nurse specialist and has worked in medical, surgical and cardiac intensive care units.

Helping teens with type 1 diabetes improve diabetes control with MyDiaText
Adolescence is a difficult period of development, made more complex for those with Type 1 diabetes mellitus (T1DM).

Diabetes-in-a-dish model uncovers new insights into the cause of type 2 diabetes
Researchers have developed a novel 'disease-in-a-dish' model to study the basic molecular factors that lead to the development of type 2 diabetes, uncovering the potential existence of major signaling defects both inside and outside of the classical insulin signaling cascade, and providing new perspectives on the mechanisms behind insulin resistance in type 2 diabetes and possibly opportunities for the development of novel therapeutics for the disease.

Tele-diabetes to manage new-onset diabetes during COVID-19 pandemic
Two new case studies highlight the use of tele-diabetes to manage new-onset type 1 diabetes in an adult and an infant during the COVID-19 pandemic.

Genetic profile may predict type 2 diabetes risk among women with gestational diabetes
Women who go on to develop type 2 diabetes after having gestational, or pregnancy-related, diabetes are more likely to have particular genetic profiles, suggests an analysis by researchers at the National Institutes of Health and other institutions.

Maternal gestational diabetes linked to diabetes in children
Children and youth of mothers who had gestational diabetes during pregnancy are at increased risk of diabetes themselves, according to new research published in CMAJ (Canadian Medical Association Journal).

Two diabetes medications don't slow progression of type 2 diabetes in youth
In youth with impaired glucose tolerance or recent-onset type 2 diabetes, neither initial treatment with long-acting insulin followed by the drug metformin, nor metformin alone preserved the body's ability to make insulin, according to results published online June 25 in Diabetes Care.

People with diabetes visit the dentist less frequently despite link between diabetes, oral health
Adults with diabetes are less likely to visit the dentist than people with prediabetes or without diabetes, finds a new study led by researchers at NYU Rory Meyers College of Nursing and East Carolina University's Brody School of Medicine.

Read More: Diabetes News and Diabetes Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to